Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy

The human immunodeficiency virus (HIV) type-1 non-nucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by CYP2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Pharmacol Ther
Glavni autori: Desta, Zeruesenay, Gammal, Roseann S., Gong, Li, Whirl-Carrillo, Michelle, Gaur, Aditya H., Sukasem, Chonlaphat, Hockings, Jennifer, Myers, Alan, Swart, Marelize, Tyndale, Rachel, Masimirembwa, Collen, Iwuchukwu, Otito F., Chirwa, Sanika, Lennox, Jeffrey, Gaedigk, Andrea, Klein, Teri, Haas, David W.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6739160/
https://ncbi.nlm.nih.gov/pubmed/31006110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1477
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items